These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 10353890)

  • 1. No evidence for serosubtype-restricted protection among teenagers vaccinated with the Norwegian group B outer membrane vesicle vaccine.
    Wedege E; Nokleby H; Bjune G
    J Infect Dis; 1999 Jul; 180(1):242; author reply 242-3. PubMed ID: 10353890
    [No Abstract]   [Full Text] [Related]  

  • 2. A new variant of serosubtype P1.16 in Neisseria meningitidis from Norway, associated with increased resistance to bactericidal antibodies induced by a serogroup B outer membrane protein vaccine.
    Rosenqvist E; Høiby EA; Wedege E; Caugant DA; Frøholm LO; McGuinness BT; Brooks J; Lambden PR; Heckels JE
    Microb Pathog; 1993 Sep; 15(3):197-205. PubMed ID: 7505873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of an efficacy trial with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway.
    Bjune G; Grønnesby JK; Høiby EA; Closs O; Nøkleby H
    NIPH Ann; 1991 Dec; 14(2):125-30; discussion 130-2. PubMed ID: 1812425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.
    Holst J; Martin D; Arnold R; Huergo CC; Oster P; O'Hallahan J; Rosenqvist E
    Vaccine; 2009 Jun; 27 Suppl 2():B3-12. PubMed ID: 19481313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meningococcal vaccines.
    Poolman JT
    J Med Microbiol; 1988 Jul; 26(3):170-2. PubMed ID: 3134548
    [No Abstract]   [Full Text] [Related]  

  • 6. Meningococcal group B vaccine trial in Norway 1981--1982. Preliminary report of results available November 1982.
    Frøholm LO; Berdal BP; Bøvre K; Gaustad P; Harboe A; Holten E; Høiby EA; Lystad A; Omland T; Frasch CE
    NIPH Ann; 1983 Dec; 6(2):133-8. PubMed ID: 6427703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Passive protection in the infant rat protection assay by sera taken before and after vaccination of teenagers with serogroup B meningococcal outer membrane vesicle vaccines.
    Toropainen M; Saarinen L; Wedege E; Bolstad K; Mäkelä PH; Käyhty H
    Vaccine; 2005 Sep; 23(40):4821-33. PubMed ID: 15970361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization with meningococcal outer-membrane protein vesicles containing lipooligosaccharide protects mice against lethal experimental group B Neisseria meningitidis infection and septic shock.
    Quakyi EK; Frasch CE; Buller N; Tsai CM
    J Infect Dis; 1999 Sep; 180(3):747-54. PubMed ID: 10438363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Class 1/3 outer membrane protein vaccine against group B, type 15, subtype 16 meningococci.
    Poolman JT; Beuvery EC; Hopman CT; Witvliet MH; Timmermans HA; Teerlink T; Zanen HC
    Dev Biol Stand; 1986; 63():147-52. PubMed ID: 3091433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABC of meningococcal diversity.
    Feavers IM
    Nature; 2000 Mar; 404(6777):451-2. PubMed ID: 10761900
    [No Abstract]   [Full Text] [Related]  

  • 11. Outer membrane vesicles (OMVs) and detoxified lipooligosaccharide (dLOS) obtained from Brazilian prevalent N. meningitidis serogroup B strains protect mice against homologous and heterologous meningococcal infection and septic shock.
    Jessouroun E; da Silveira IF; Larangeira AP; Pereira S; Fernandes SA; Rabinovitch L; Frasch CE; Castro-Faria-Neto HC; Bozza PT
    Vaccine; 2004 Jun; 22(20):2617-25. PubMed ID: 15193387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Typing of group-B Neisseria meningitidis with monoclonal antibodies in the whole-cell ELISA.
    Abdillahi H; Poolman JT
    J Med Microbiol; 1988 Jul; 26(3):177-80. PubMed ID: 3134550
    [No Abstract]   [Full Text] [Related]  

  • 13. Diagnostic work with suspected cases of systemic meningococcal disease in the Norwegian serogroup B vaccine protection trials.
    Holten E; Bruun JN; Hellum KB; Maeland JA
    NIPH Ann; 1991 Dec; 14(2):103-6; discussion 121-3. PubMed ID: 1812423
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks.
    Taha MK; Zarantonelli ML; Alonso JM; Naess LM; Holst J; Feiring B; Rosenqvist E
    Vaccine; 2007 Mar; 25(14):2537-8. PubMed ID: 16460845
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Safety review: Two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease, Nokleby H, Aavitsland P, O'Hallahan J, Feiring B, Tilman S, Oster P. Vaccine 2007;25(16):3080-4.
    Lennon D
    Vaccine; 2007 Sep; 25(39-40):6833; author reply 6833-4. PubMed ID: 17630051
    [No Abstract]   [Full Text] [Related]  

  • 16. [Why and when to vaccinate against meningococcal disease].
    Humble M
    Nord Med; 1984; 99(10):248-50, 253. PubMed ID: 6436785
    [No Abstract]   [Full Text] [Related]  

  • 17. Outbreaks of group B meningococcal disease--Florida, 1995 and 1997.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1998 Oct; 47(39):833-7. PubMed ID: 9780239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse events following vaccine or placebo injection in an efficacy trial of an outer membrane vesicle vaccine against group B meningococcal disease in Norwegian secondary schools 1988-1991.
    Aavitsland P; Bjune G; Aasen S; Halvorsen S
    NIPH Ann; 1991 Dec; 14(2):133-4; discussion 136-7. PubMed ID: 1812426
    [No Abstract]   [Full Text] [Related]  

  • 19. Adjuvant can improve protection induced by OMV vaccine against Neisseria meningitidis serogroups B/C in neonatal mice.
    Fukasawa LO; Dias WO; Schenkman RP; Raw I; Tanizaki MM
    FEMS Immunol Med Microbiol; 2004 Jul; 41(3):205-10. PubMed ID: 15196569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent developments in vaccines to prevent meningococcal serogroup B infections.
    Vermont CL; van den Dobbelsteen GP; de Groot R
    Curr Opin Mol Ther; 2003 Feb; 5(1):33-8. PubMed ID: 12669468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.